Emerging Concepts on the Role of Immunotherapy in NSCLC
Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.
Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC
Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.
NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients
Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.
Immunotherapy in NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations
Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.
Treatment Approaches for NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations
Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.
Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC
Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.
Applying Molecular Biomarkers in Treatment Decision Making in NSCLC
An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.
Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC
Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.
The Role of Molecular Testing In Metastatic NSCLC
Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.
IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations
Closing out her discussion on the management of actionable mutations in NSCLC, Meghan Mooradian, MD, highlights the detection and implications of KRAS/TP53 mutations.
Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations
Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.
Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?
Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.
Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer
Meghan Mooradian, MD, highlights best practices for identifying molecular alterations in NSCLC and addresses barriers to testing.
Overview of Actionable Mutations and Molecular Profiling in NSCLC
Expert perspective on the current landscape of actionable mutations and molecular profiling in non–small cell lung cancer management.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512